世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

世界のワクチン製造受託市場 2017-2027年:主要国、技術、企業

Global Vaccine Contract Manufacturing Market Report 2017-2027

Leading Countries, Technologies and Companies

 

出版社 出版年月電子版価格 ページ数図表数
Visiongain
ヴィジョンゲイン社
2017年2月GBP2,999
部署ライセンス
154 74

サマリー

世界のワクチン製造受託市場を分析・予測したVisiongainの市場調査報告書です。

Report Details

The global vaccine contract manufacturing market is expected to grow at a CAGR of 8.9% from 2016-2021 and CAGR of 9.2% from 2021-2027. The market is expected to grow at a CAGR of 9.1% from 2016 to 2027. The market is estimated at $816m in 2016, and $2117m in 2027.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 154-page report you will receive 74 charts – all unavailable elsewhere.

The 155-page report provides clear detailed insight into the global vaccine contract manufacturing market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope
• Revenue and growth forecasts to 2027 for the global vaccine market and market shares of the submarkets: paediatric vaccines, adult vaccines, influenza vaccines and therapeutic vaccines

• Revenue and growth forecasts to 2027 for the global vaccine contract manufacturing market

• Revenue and growth forecasts to 2027 for the leading national markets:
- United States
- Germany
- France
- United Kingdom
- Italy
- Spain
- Japan
- Brazil
- Russia
- China
- India
- Rest of the World

• Revenue and growth forecasts to 2027 for the leading players in the vaccine contract manufacturing market:
- Baxter BioPharma Solutions
- Boehringer Ingelheim
- Catalent
- Charles River Laboratories
- IDT Biologika
- Lonza
- Meridian Life Science
- Sigma Aldrich Fine Chemicals
- Merck
- Synco Bio Partners

• Analysis of what stimulates and restrains the global vaccine contract manufacturing market



目次

Table of Contents

1. Report Overview
1.1 World Vaccine Contract Manufacturing Market Highlights
1.2 Why You Should Read This Report?
1.3 How This Report Delivers
1.4 Key Questions Answered by This Analytical Report
1.5 Who is This Report For?
1.6 Methodology
1.7 Frequently Asked Questions (FAQ)
1.8 Associated Visiongain Reports
1.9 About Visiongain

2. Introduction to Vaccines
2.1 The History of Vaccines
2.2 How Do Vaccines Work?
2.2.1 Artificial Immunity
2.3 Types of Vaccine
2.3.1 Live, Attenuated Vaccines (LAVs)
2.3.2 Recombinant Live Vaccines
2.3.3 Inactivated Vaccines
2.3.4 Toxoid Vaccines
2.3.5 Subunit Vaccines
2.3.6 Conjugate Vaccines
2.3.7 Recombinant Subunit Vaccines
2.3.8 DNA Vaccines
2.3.9 Recombinant Vector Vaccines
2.3.10 Therapeutic Vaccines
2.4 Diseases Preventable with Vaccines
2.5 The Rise of the Vaccines Market
2.6 Technological and Regulatory Improvements

3. Vaccine Manufacturing Technologies, 2017
3.1 Summary of Vaccine Technology Trends
3.2 New Substrates for Vaccine Production
3.2.1 Shift towards Cell-Based Manufacturing Technology
3.2.2 Benefits of Cell-Based Techniques
3.2.3 Mammalian Cell Lines
3.2.3.1 MCDK (Madin Darby Canine Kidney Cells)
3.2.3.2 Vero Cells
3.2.3.3 PerC6 Cells
3.2.4 Avian-Derived Cell Lines
3.2.4.1 EB66 Stem Cell Technology: Vivalis
3.2.5 Plant-Based Vaccines
3.2.5.1 Medicago’s Proficia VLP Vaccine Technology
3.2.6 Insect Egg-Based Production Systems
3.2.6.1 Novavax
3.2.6.2 Protein Sciences Corporation (PSC)
3.3 Next-Generation Expression Systems and Vectors: Increasing Production Yield
3.3.1 AdVac Technology: Crucell
3.3.2 AdCEV Vectors: AfriVax
3.3.3 Pfenex Expression Technology: Pfenex
3.4 Equipment Trends
3.4.1 The Shift Towards Disposable Single-use Equipment
3.4.2 Bioreactors and Vaccine Production
3.4.2.1 Single-Use Bioreactors
3.4.2.2 Main Applications of Disposable Bioreactors
3.4.2.3 Current Single-Use Bioreactor Systems on the Market
3.5 Prefilled Syringes and Vaccines
3.5.1 Growing Market for Pre-Filled Syringes
3.5.2 Pre-Filled Vaccine Products
3.5.3 Drivers and Restraints for Pre-Filled Syringes
3.5.4 Product Stability and Quality Assurance Programme
3.5.4.1 Paediatric H1N1 Vaccine
3.5.4.2 Reported Challenges Flu Vaccines
3.5.4.3 Novartis' Agriflu and Fluad Ban is Lifted
3.5.4.4 Baxter Flu Vaccine and Side Effects
3.5.4.5 Reported Shelf Life with H1N1 Vaccine
3.6 Lyophilisation and Vaccine Manufacturing
3.6.1 Lyophilisation of Vaccines Will Increase
3.7 Cell Media Can Improve Virus Yield

4. The Global Vaccine Manufacturing Market 2017-2027
4.1 Overview of the Global Vaccine Manufacturing Market 2017-2027
4.2 World Vaccine Market Forecast 2017-2027
4.3 The Global Vaccine Market by Submarket, 2016 and 2017
4.4 Growth in Vaccine Market Will Drive Efficiency in Vaccine Manufacturing
4.5 Paediatric Vaccines Market Overview
4.6 Adult Prophylactic Vaccines Market Overview
4.7 Influenza Vaccines Market Overview
4.8 Therapeutic Vaccines Market Overview

5. The Global Vaccine Contract Manufacturing 2017-2027
5.1 Outsourcing in the Pharmaceutical and Biotechnology Industry
5.1.1 Reasons to Outsource
5.1.2 Benefits of Outsourcing
5.1.3 The Challenges in Outsourcing Vaccine Manufacturing
5.1.4 Why Should Companies Outsource Vaccine Manufacturing?
5.1.5 Strategic Outsourcing vs. Tactical Outsourcing
5.1.6 Virtual Companies
5.2 Contract Manufacturing Organisations (CMOs)
5.2.1 Manufacturing Services Offered by CMOs
5.2.2 Vaccine Manufacturing Activities Typically Outsourced
5.3 The Pharmaceutical Contract Manufacturing Market: Overall Revenue Forecast 2016-2027
5.4 Contract Manufacturing Market for Vaccines 2016-2027
5.4.1 Market Size for Contract Manufacturing of Vaccines 2016
5.4.2 Vaccine Contract Manufacturing Market Forecast 2016-2027

6. The Leading National Markets for Vaccine Contract Manufacturing, 2017-2027
6.1 The Leading National Markets for Vaccine Contract Manufacturing
6.2 The Leading National Markets for Vaccine Contract Manufacturing, 2016-2017
6.3 The Leading National Markets for Vaccine Contract Manufacturing, 2016-2027
6.3.1 The US Vaccine Contract Manufacturing Market Forecast, 2016-2027
6.3.2 The EU5 Vaccine Contract Manufacturing Market, 2016 and 2017
6.3.2.1 The EU5 Vaccine Contract Manufacturing Market, 2016-2027
6.3.2.2 The German Vaccine Contract Manufacturing Market, 2016-2027
6.3.2.3 The Italian Vaccine Contract Manufacturing Market, 2016-2027
6.3.2.4 The UK Vaccine Contract Manufacturing Market, 2016-2027
6.3.2.5 The French Vaccine Contract Manufacturing Market, 2016-2027
6.3.2.6 The Spanish Vaccine Contract Manufacturing Market, 2016-2027
6.3.3 The Japanese Vaccine Contract Manufacturing Market, 2016-2027
6.3.4 The Chinese Vaccine Contract Manufacturing Market, 2016-2027
6.3.5 The Indian Vaccine Contract Manufacturing Market, 2016-2027
6.3.6 The Russian Vaccine Contract Manufacturing Market, 2016-2027
6.3.7 The Brazilian Vaccine Contract Manufacturing Market, 2016-2027

7. Leading Vaccine Contract Manufacturing Companies, 2017-2027
7.1 Leading Vaccine Contract Manufacturing Organisations
7.2 Baxter BioPharma Solutions
7.3 Boehringer Ingelheim
7.3.1 Recent Financial Performance
7.3.2 Ben Venue Laboratories
7.3.3 Manufacturing Deals 2011-2017
7.4 Catalent
7.4.1 Recent Financial Performance
7.4.2 Catalent: Financial Performance by Segment, 2011-2016
7.4.3 Catalent Injectable Vaccines
7.4.4 Catalent: Zydis Technology
7.4.5 Regional Market Expansion Strategy
7.5 Charles River Laboratories
7.5.1 Recent Financial Performance, 2011-2014
7.5.2 Financial Performance by Segment, 2010-2015
7.5.3 Recent Financial Performance, 2015
7.5.4 Vaccine Manufacturing Services
7.5.5 Charles River Avian Vaccine Services
7.5.6 Vaccine Manufacturing Expansion
7.5.7 Outlook and Early Stage Restructuring
7.5.8 Partnerships
7.5.8.1 Partnership with AstraZeneca
7.5.8.2 Partnership with Batavia
7.6 IDT Biologika GmbH
7.7 Lonza
7.7.1 Recent Financial Performance
7.7.2 Financial Performance in H1 2015
7.7.3 Manufacturing Division Restructuring
7.8 Meridian Life Science
7.8.1 Recent Financial Performance, 2010-2016
7.8.2 Recent Financial Performance by Segment, 2011-2016
7.9 Sigma-Aldrich Fine Chemicals (SAFC) (Merck KGaA)
7.10 SynCo Bio Partners
7.10.1 Recent Developments
7.10.1.1 Expansion of Facilities
7.10.1.2 FDA Approval of Partner Application

8. Vaccine Manufacturing Market: World Market Trends 2017-2027
8.1 Vaccine Contract Manufacturing Industry Trends
8.2 Strengths
8.2.1 Many Companies Cannot Afford In-house Capabilities
8.2.2 Outsourcing Improves Time to Market
8.2.3 Manufacturers Get Access to Specialised Technologies
8.2.4 Shift Towards Emerging Markets as Favourable Outsourcing Destinations
8.3 Weaknesses
8.3.1 Mass Vaccine Manufacturing Kept In-house
8.3.2 A Highly-Fragmented Vaccine Contract Manufacturing Market
8.3.3 An Unpredictable Supply and Demand Business Model
8.4 Opportunities
8.4.1 Many Vaccines in the Product Pipeline
8.4.2 Emerging Market’s Growing Demand for Vaccines
8.4.2.1 Dynamic Change: Emerging Markets are Major Vaccine Developers
8.4.3 Changing World Demographics
8.5 Threats
8.5.1 Post Recession: Biotech Suffer from Severe Cuts in Capital Funding
8.5.2 The Public are Slow to Accept Novel Technologies
8.5.3 Perception of Risk by the Original Vaccine Manufacturers

9. Conclusion
9.1 Overview
9.2 Regulatory and Quality Standards Create High Barriers of Entry
9.3 Emerging Markets Will Show Stronger Growth

Appendix A
About Visiongain
Appendix B
Visiongain report evaluation form

List of Figures

Figure 3.1 Influenza Vaccine Production Using a Cell-Based Manufacturing Method
Figure 3.2 Medicago’s Product Pipeline
Figure 3.3 Novavax’ Insect Egg-Based Vaccine Production Process
Figure 3.4 Pre-filled Syringes Market: Drivers and Restraints, 2017-2027
Figure 4.1 The Global Vaccine Market Forecast: Revenue ($bn) and AGR (%) 2016-2027
Figure 4.2 The Global Vaccine Market: Market Share by Submarket (%), 2017
Figure 5.1 Selected Tasks Outsourced in the Pharmaceutical and Biotech Industry
Figure 5.2 The Global Pharmaceutical Contract Manufacturing Forecast: Revenue ($bn), 2016, 2021 and 2027
Figure 5.3 The Global Vaccine Contract Manufacturing Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 6.1 The Leading National Vaccine Contract Manufacturing Markets: Market Share (%) by Region, 2016
Figure 6.2 The US Vaccine Contract Manufacturing Forecast: Revenue ($m) and AGR (%),2016-2027
Figure 6.3 The EU5 Vaccine Contract Manufacturing Markets: Market Share (%) by Country, 2017
Figure 6.4 The EU5 Vaccine Contract Manufacturing Market Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 6.5 The German Vaccine Contract Manufacturing Market Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 6.6 The Italian Vaccine Contract Manufacturing Market Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 6.7 The UK Vaccine Contract Manufacturing Market Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 6.8 The French Vaccine Contract Manufacturing Market Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 6.9 The Spanish Vaccine Contract Manufacturing Market Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 6.10 The Japanese Vaccine Contract Manufacturing Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Figure 6.11 The Chinese Vaccine Contract Manufacturing Market Forecast: Revenue ($m) and AGR (%) 2016-2027
Figure 6.12 The Indian Vaccine Contract Manufacturing Market Forecast: Revenue ($m) and AGR (%) 2016-2027
Figure 6.13 The Russian Vaccine Contract Manufacturing Market Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 6.14 The Brazilian Vaccine Contract Manufacturing Market Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 7.1 Boehringer Ingelheim: Biopharmaceuticals Revenue ($m) and Annual Growth Rate (%), 2010-2015
Figure 7.2 Catalent: Revenue ($m) and AGR (%), 2010-2015
Figure 7.3 Catalent: Revenue ($m) by Segment, 2011-2016
Figure 7.4 Catalent: Marker Shares (%) by Segment, 2016
Figure 7.5 Charles River Laboratories: Revenue ($bn) and AGR (%), 2010-2015
Figure 7.6 Charles River Laboratories: Quarterly Revenue ($m) by Segment, 2014-2015
Figure 7.7 Lonza Custom Manufacturing: Revenue ($m )and AGR (%), 2010-2015
Figure 7.8 Meridian Bioscience: Revenue ($m), and AGR (%), 2010-2016
Figure 7.9 Meridian Bioscience: Revenue ($m) by Segment, 2011-2016
Figure 7.10 Meridian Bioscience: Market Share (%) by Segment,2016
Figure 8.1 Drivers and Restraints for the Vaccine Contract Manufacturing Sector, 2017-2027

List of Tables
Table 2.1 Timeline of Key Events in Vaccine Development, c.1000 AD – Present
Table 3.1 Vaccine Development Pipeline Using Crucell’s AdVac Technology
Table 3.2 Benefits and Drawbacks of Using Disposable Technology for Vaccine Production
Table 3.3 Companies Providing Disposable Biomanufacturing Platforms/Systems
Table 3.4 Some Leading Pre-Filled Syringe Vaccine Products
Table 3.5 Prominent Lyophilised Vaccines
Table 3.6 Examples of Serum-Free Media for Vaccine Manufacturing
Table 4.1 The Global Vaccine Market Forecast: Revenue ($bn), AGR (%) and CAGR (%) 2016-2027
Table 4.2 The Global Vaccine Market: Revenue ($bn) and Market Share by Submarket (%), 2016-2017
Table 5.1 The Global Vaccine Contract Manufacturing Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 6.1 The Leading National Vaccine Contract Manufacturing Markets Forecast: Revenue ($m) and Market Share (%), 2016-2017
Table 6.2 The Leading National Vaccine Contract Manufacturing Markets Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 6.3 The Leading National Vaccine Contract Manufacturing Markets Forecast: Market Shares (%), 2016 and 2027
Table 6.4 The US Vaccine Contract Manufacturing Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 6.5 The EU5 National Vaccine Contract Manufacturing Markets: Revenue ($m) and Market Share (%) by Country, 2016-2017
Table 6.6 The EU5 Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 6.7 The German Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 6.8 The Italian Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 6.9 The UK Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 6.10 The French Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 6.11 The Spanish Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 6.12 The Japanese Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 6.13 The Chinese Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 6.14 The Indian Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 6.15 The Russian Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 6.16 The Brazilian Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 7.1 Boehringer Ingelheim: Biopharmaceuticals Revenue ($m) and Annual Growth Rate (%), 2010-2015
Table 7.2 Catalent: Revenue($m) and AGR (%), 2010-2016
Table 7.3 Catalent by Segment: Revenue($m), AGR (%), and Intersegment Revenue Eliminations, 2011-2016
Table 7.4 Charles River Laboratories: Revenue ($bn) and AGR (%), 2010-2015
Table 7.5 Charles River Laboratories: Newly Revised Reportable Segments
Table 7.6 Charles River Laboratories: Revenue ($bn) by Segment, 2010-2012
Table 7.7 Charles River Laboratories: Revenue ($bn) by Segment, 2013-2015
Table 7.8 Charles River Laboratories: Quarterly Revenue ($m) by Segment, 2015
Table 7.9 Charles River Laboratories: cGMP Vaccine Manufacturing and Testing Capabilities
Table 7.10 Lonza Custom Manufacturing: Revenue ($m) and AGR (%), 2010-2015
Table 7.11 Meridian Bioscience: Revenue ($m), AGR (%), 2010-2016
Table 7.12 Meridian Bioscience: Revenue ($m) and AGR (%) by Segment, 2011-2017
Table 7.13 SynCo Bio Partners Capabilities
Table 8.1 SWOT Analysis of the Vaccine Contract Manufacturing Market, 2

 

Companies Listed

Aeras Global
AfriVax
AmProtein
Antigenics Inc.
Artelis
AstraZeneca
ATM Life Sciences
AVEO Pharmaceuticals
Baxter BioPharma Solutions
Bayer
Beijing Tiantan Biological Productions
Berna Biotech
Bharat Biotech International Limited
Binnopharm
BioKangtai
Biomedical Advanced Research and Development Authority (BARDA)
Biovest
Boehringer Ingelheim Biopharmaceuticals (China)
Cadila Pharmaceuticals
Catalent
Cellexus Limited
Center for Disease Control (CDC)
China Food and Drug Administration (CFDA)
Crucell
CSL Biotherapies
Daiichi Sankyo
Dalian Hissen Bio-Pharm
Defense Advanced Research Projects Agency (DARPA)
Food and Drug Administration (FDA)
FiberCell
GE Healthcare
GlaxoSmithKline
Hikma
Hualan Biological Bacterin
Hyclone
Institut Pasteur
Intercell Corporation
Invitrogen
Irvine Scientific
Kuhner
LG Life Sciences
Lonza
Medicago
Meissner Filtration
Merck
Merck Serono
Micron Technologies
Millipore
Mitsubishi Tanabe Pharma (MTPC)
MorphoSys
MP Biomedicals
National Institute of Allergy and Infectious Diseases (NIAID)
Novartis
Novavax
Organon Teknika Corporation
Pall Life Sciences
Paragon Bioservices
Patheon
PBS Biotech
Pfenex
Pfizer
Philip Morris Investments
Pierre-Guerin Biolafitte
Protein Sciences Corporation
Refine Technology
Sanofi
Sartorius Stedim
Shanghai Zhangjiang Biotech and Pharmaceutical Base Development Co. Ltd.
Sigma Aldrich
Thermo Fisher
U.S Department of Homeland Security
U.S. Department of Health and Human Services Office
Vector Solutions
Vivalis
Wave Biotech
World Health Organisation (WHO)
Wyeth Pharmaceuticals
Xcellerex
Xencor

 

ページTOPに戻る

あなたが最近チェックしたレポート一覧

  • 最近チェックしたレポートはありません。

お問合は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのお問合せはこちらのフォームから承ります

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

<無料>メルマガに登録する

 

 

ページTOPに戻る